CC
CDTX

Checkpoint Capital’s Cidara Therapeutics CDTX Stock Holding History

Checkpoint Capital’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-104,380
Closed -$2.25M – 9
2025
Q1 		$2.25M Sell
104,380
-92,569
-47% -$2.06M 1.23% 11
2024
Q4 		$5.11M Buy
196,949
+14,523
+8% +$236K 2.6% 10
2024
Q3 		$1.96M Buy
182,426
+37,009
+25% +$444K 0.97% 12
2024
Q2 		$1.74M Buy
+145,417
New +$1.99M 1.05% 12

Other funds holding CDTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Checkpoint Capital's CDTX Position: Q2 2025 in Review

Checkpoint Capital sold out of Cidara Therapeutics (CDTX) in Q2 2025, closing a stake of 104,380 shares — an estimated $2.25M sold.

Checkpoint Capital first reported a position in CDTX in Q2 2024 and held it in 4 quarters. The position peaked at $5.11M in Q4 2024. 109 funds tracked by Wall St. Rank hold CDTX as of Q2 2025.

  • Checkpoint Capital reported no remaining Cidara Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Checkpoint Capital sold 104,380 Cidara Therapeutics shares in Q2 2025, an estimated $2.25M.
  • Checkpoint Capital first reported a position in Cidara Therapeutics in Q2 2024 and held it in 4 quarters.
  • Checkpoint Capital's Cidara Therapeutics position peaked at $5.11M in Q4 2024.
  • 109 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2025.

Based on Checkpoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.